Therapeutics News and Research

RSS

Symposium to discuss latest scientific and clinical advances in treating non-Hodgkins lymphoma

Fifty world-renowned experts in non-Hodgkins lymphoma will convene in New York in November to present the latest scientific and clinical advances in treating a "lost generation" of sufferers-children, young adults and adolescents.

31 Oct 2012

Complix to accelerate development of CPABs against intracellular disease targets

Complix announces that it has been awarded a €1.9 million grant (approximately USD$2.4 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in Flanders).

30 Oct 2012

BioXpress, AET BioTech enter agreement to co-develop Adalimumab biosimilar

AET BioTech, the separate biosimilars business within the generic drug developer AET (Alfred E Tiefenbacher) Group and BioXpress Therapeutics SA, a Swiss-based biotechnology company developing monoclonal antibody (MAb) biosimilars have entered into an agreement for the co-development of a biosimilar version of the TNF inhibitor MAb Adalimumab.

30 Oct 2012

Sprint Bioscience, TPP partner to develop small molecule inhibitors of choline kinase for cancer

TPP Global Development Ltd (TPP) enters into a collaboration with Sprint Bioscience AB to develop small molecule inhibitors of choline kinase as human therapeutics for the treatment of cancer.

30 Oct 2012

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Celldex Therapeutics, Inc. today announced positive results demonstrating promising clinical effects in a Phase 1 study of CDX-1401 in solid tumors in combination with the toll-like receptor (TLR) agonists resiquimod and/or Poly ICLC.

30 Oct 2012

Carotid ultrasound improves risk management in rheumatoid arthritis

A trial of radiofrequency ultrasound in patients with rheumatoid arthritis has shown that carotid intima-media thickness is significantly greater in patients treated only with synthetic therapeutics compared with those who are also taking biologics.

29 Oct 2012

Cellectis announces successful programming of immune system cells to kill cancer cells

Cellectis, the genome engineering specialist, has announced successfully programming cells from the immune system (T cells) to kill cancer cells. This technological breakthrough was revealed for the first time ever on Saturday, October 27th at the congress of the ESGCT (European Society of Gene & Cell Therapy) in Versailles, outside Paris.

29 Oct 2012

Drug-eluting stents exhibit some benefits in patients over 80

Rarely tested in patients over the age of 80, a study found that drug-eluting stents exhibited some benefits over bare-metal stents, though both types of stents demonstrated a clinical benefit. Results of the XIMA trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

29 Oct 2012

St. Luke's cardiologist wins TCT 2012 Geoffrey O. Hartzler Master Clinical Operator Award

Barry D. Rutherford, MD, a world renowned interventional cardiologist, was presented the TCT 2012 Geoffrey O. Hartzler Master Clinical Operator Award in a ceremony held today during the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

29 Oct 2012

Trial finds benefits in using radial approach for primary angioplasty in heart attack patients

A study found several benefits in using the radial artery in the arm as the entry point for angioplasty or percutaneous coronary intervention (PCI) compared to the femoral artery in the leg. Results of the STEMI-RADIAL trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

29 Oct 2012

Intracoronary and IV abciximab during angioplasty do not result in differences in myocardial damage

A study confirmed no differences in various measures of heart damage, according to cardiac magnetic resonance (MRI) imaging, in patients receiving the anti-clotting medication abxicimab directly into the heart (intracoronary) compared to those receiving it intravenously (IV).

26 Oct 2012

PFO closure with investigational device may prevent cryptogenic ischemic stroke

A clinical trial indicates that using an investigational medical device to close a PFO, or "hole in the heart," may be superior to medical management alone in the prevention of a repeated stroke.

26 Oct 2012

Study identifies essential mechanism that regulates calcium flow into mitochondria

Most healthy cells rely on a complicated process to produce the fuel ATP. Knowing how ATP is produced by the cell's energy storehouse - the mitochondria -- is important for understanding a cell's normal state, as well as what happens when things go wrong, for example in cancer, cardiovascular disease, neurodegeneration, and many rare disorders of the mitochondria.

26 Oct 2012

UWCCC enrolls first patient in Phase 1-2 PET imaging trial of LIGHT for solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Center, a leading oncology research institution, has enrolled the first patient in a Phase 1-2 positron emission tomography (PET) imaging trial of I-124-CLR1404, a cancer-targeted PET imaging agent, in patients with nine solid tumor types, including triple negative breast, soft tissue sarcoma, colorectal, gastric, esophageal, prostate, ovarian, pancreatic and head & neck cancer.

26 Oct 2012

LVEDP-guided hydration effectively prevents CI-AKI in patients undergoing cardiac catheterization

A hydration regimen tailored to the patient's fluid status was effective in reducing damage to kidneys in patients undergoing cardiac catheterization, according to a study presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

26 Oct 2012

FFR-guided PCI appears to be economically attractive than medical therapy for stable CAD

A strategy of up-front percutaneous coronary intervention (PCI) for lesions confirmed to be obstructive by fractional flow reserve (FFR) was shown to be cost-effective in terms of quality-adjusted life years when compared to medical therapy alone.

26 Oct 2012

USPTO issues patent to Tobira’s cenicriviroc for treatment of HIV-1 infection

Tobira Therapeutics, Inc., developer of innovative antiretroviral therapies for HIV, today announced the United States Patent and Trademark Office has issued patent 8,183,273, claiming compositions of matter of a broad family of compounds with activity against chemokine receptors CCR5 and CCR2.

26 Oct 2012

Durata completes target enrollment in dalbavancin Phase 3 trial for ABSSSI

Durata Therapeutics today announced that it has completed its target enrollment for DISCOVER 2 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response"), the second global, Phase 3 clinical trial of Durata's lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria.

26 Oct 2012

Prasugrel reduces cardiovascular events among patients managed medically for ACS

A study has found that the anti-clotting medication prasugrel reduced cardiovascular events among patients who present with an acute coronary syndrome and are managed medically after an angiogram is performed to determine coronary anatomy.

25 Oct 2012

TAVR procedure yields lower mortality rates for patients with aortic stenosis after three years

A study found that transcatheter aortic valve replacement (TAVR) yielded lower mortality rates after three years compared with medical therapy in patients deemed to be ineligible for conventional aortic valve surgery.

25 Oct 2012

Therapeutics News and Research

Symposium to discuss latest scientific and clinical advances in treating non-Hodgkins lymphoma

Complix to accelerate development of CPABs against intracellular disease targets

BioXpress, AET BioTech enter agreement to co-develop Adalimumab biosimilar

Sprint Bioscience, TPP partner to develop small molecule inhibitors of choline kinase for cancer

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Carotid ultrasound improves risk management in rheumatoid arthritis

Cellectis announces successful programming of immune system cells to kill cancer cells

Drug-eluting stents exhibit some benefits in patients over 80

St. Luke's cardiologist wins TCT 2012 Geoffrey O. Hartzler Master Clinical Operator Award

Trial finds benefits in using radial approach for primary angioplasty in heart attack patients

Intracoronary and IV abciximab during angioplasty do not result in differences in myocardial damage

PFO closure with investigational device may prevent cryptogenic ischemic stroke

Study identifies essential mechanism that regulates calcium flow into mitochondria

UWCCC enrolls first patient in Phase 1-2 PET imaging trial of LIGHT for solid tumors

LVEDP-guided hydration effectively prevents CI-AKI in patients undergoing cardiac catheterization

FFR-guided PCI appears to be economically attractive than medical therapy for stable CAD

USPTO issues patent to Tobira’s cenicriviroc for treatment of HIV-1 infection

Durata completes target enrollment in dalbavancin Phase 3 trial for ABSSSI

Prasugrel reduces cardiovascular events among patients managed medically for ACS

TAVR procedure yields lower mortality rates for patients with aortic stenosis after three years

Industry Focus eBook - Microbiome (1st edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News